Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Glatigny, Simon ^a,b   Duhen, Rebekka ^a,b   Arbelaez, Carlos ^a,b   Kumari, Swarnima ^a,b   Bettelli, Estelle ^a,b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL; AUTOIMMUNITY; C57BL MOUSE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CYTOLOGY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; ANTIGENS, CD11A; AUTOIMMUNITY; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; INTEGRIN ALPHA4; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 84941778910     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07834     Document Type: Article

References (34)

1. Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., Mills, K. H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162, 1-11 (2010).
2. Jager, A., Dardalhon, V., Sobel, R. A., Bettelli, E., Kuchroo, V. K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183, 7169-7177 (2009).
3. Stromnes, I. M., Cerretti, L. M., Liggitt, D., Harris, R. A., Goverman, J. M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 14, 337-342 (2008).
4. Sakaguchi, S. Naturally arising Foxp3-expressing CD251CD41regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6, 345-352 (2005).
5. Lafaille, J. J., Nagashima, K., Katsuki, M., Tonegawa, S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78, 399-408 (1994).
6. Stephens, L. A., Malpass, K. H., Anderton, S. M. Curing CNS autoimmune disease with myelin-reactive Foxp31Treg. Eur J Immunol 39, 1108-1117 (2009).
7. Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63-66 (1992).
8. Ransohoff, R M. Natalizumab for multiple sclerosis.NEngl JMed 356, 2622-2629 (2007).
9. Glatigny, S., Duhen, R., Oukka, M., Bettelli, E. Cutting edge: loss of alpha4 integrin expression differentially affects the homing of Th1 and Th17 cells. J Immunol 187, 6176-6179 (2011).
10. Rothhammer, V. et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J Exp Med 208, 2465-2476 (2011).
11. Chaudhry, A., Rudensky, A. Y. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest 123, 939-944 (2013).
12. Scott, L. M., Priestley, G. V., Papayannopoulou, T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 23, 9349-9360 (2003).
13. Mittelbrunn, M. et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA 101, 11058-11063 (2004).
14. Sato, T., Tachibana, K.,Nojima, Y.,D'Avirro, N. Morimoto, C. Role of theVLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol 155, 2938-2947 (1995).
15. Gultner, S. et al. Reduced Treg frequency in LFA-1-deficient mice allows enhanced T effector differentiation and pathology in EAE. Eur J Immunol 40, 3403-3412 (2010).
16. Berlin-Rufenach, C. et al. Lymphocyte migration in lymphocyte functionassociated antigen (LFA)-1-deficient mice. J Exp Med 189, 1467-1478 (1999).
17. Niino, M. et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59, 748-754 (2006).
18. Stuve, O. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59, 743-747 (2006).
19. Anderton, S. M. Treg and T-effector cells in autoimmune CNS inflammation: a delicate balance, easily disturbed. Eur J Immunol 40, 3321-3324 (2010).
20. Cabbage, S. E. et al. Regulatory T cells maintain long-term tolerance to myelin basic protein by inducing a novel, dynamic state of T cell tolerance. J Immunol 178, 887-896 (2007).
21. Furtado, G. C. et al. Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182, 122-134 (2001).
22. Viglietta, V., Baecher-Allan, C., Weiner, H. L., Hafler, D. A. Loss of functional suppression by CD41CD251 regulatory T cells in patients with multiple sclerosis. J Exp Med 199, 971-979 (2004).
23. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
24. Stenner, M. P. et al. Effects of natalizumab treatment on Foxp31 T regulatory cells. PLoS One 3, e3319 (2008).
25. Kleinewietfeld, M. et al. CD49d provides access to "untouched" human Foxp31 Treg free of contaminating effector cells. Blood 113, 827-836 (2009).
26. Axtell, R. C. et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16, 406-412 (2010).
27. Ding, Y., Xu, J., Bromberg, J. S. Regulatory T cell migration during an immune response. Trends Immunol 33, 174-180 (2012).
28. Nguyen, V. H. et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 109, 2649-2656 (2007).
29. Rudensky, A. Y., Campbell, D. J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 203, 489-492 (2006).
30. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366, 1870-1880 (2012).
31. Stuve, O. et al. Altered CD41/CD81 T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63, 1383-1387 (2006).
32. Hu, X., Wohler, J. E., Dugger, K. J., Barnum, S. R. beta2-integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol 87, 397-403 (2010).
33. Dugger, K. J., Zinn, K. R.,Weaver, C., Bullard, D. C., Barnum, S. R. Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis. J Neuroimmunol 206, 22-27 (2009).
34. Chaudhry, A. et al. CD41 regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986-991 (2009).